Kolexia
Baudin Eric
Endocrinologie
Gustave-Roussy
Villejuif, France
417 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs neuroendocrines Tumeurs de la thyroïde Carcinome corticosurrénalien Métastase tumorale Tumeurs du pancréas Phéochromocytome Carcinome neuroendocrine Tumeurs corticosurrénaliennes

Industries

Ipsen
13 collaboration(s)
Dernière en 2022
Advanced Accelerator Applications
7 collaboration(s)
Dernière en 2022
ADVANCED ACCELERATOR APPLICATIONS
3 collaboration(s)
Dernière en 2023
HRA Pharma
2 collaboration(s)
Dernière en 2022

Dernières activités

Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet (London, England)   22 février 2024
ACTION-1: Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
Essai Clinique (RayzeBio, Inc.)   31 janvier 2024
Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population & literature review.
The Journal of clinical endocrinology and metabolism   30 janvier 2024
EPAS1-mutated paragangliomas associated with haemoglobin disorders.
British journal of haematology   09 janvier 2024
Intraoperative Parathyroid Gland Identification Using Autofluorescence Imaging in Thyroid Cancer Surgery with Central Neck Dissection: Impact on Post-Operative Hypocalcemia.
Cancers   29 décembre 2023
Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
JCO precision oncology   25 décembre 2023
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas: A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Essai Clinique (Celgene)   07 décembre 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4 FoxP3 intratumoral T-cells in primary human cancers.
Journal of experimental & clinical cancer research : CR   06 décembre 2023
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Trials   30 novembre 2023
OPALINE: AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Essai Clinique (Pfizer)   09 novembre 2023